EU GMP Guideline Revision To Impact Chinese Pharmaceutical Export
This article was originally published in PharmAsia News
Executive Summary
The European Union has revised its Good Manufacturing Practices guideline to include quality risk management, which will come into effect in July. Analysts note that relevant corporations in China should attach great importance to this development because quality risk management represents the domestic pharmaceutical industry's weakest link. The new demand may impact the export of pharmaceutical preparations as well as medical raw materials. An expert involved in setting China's New GMP Inspectional Guidelines says that the standards follow closely those of the U.S. FDA and EU; thus the guidelines can almost satisfy the new EU GMP requirements. (Click here for more - Chinese Language)
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.